Hogarty G E, Schooler N R, Ulrich R, Mussare F, Ferro P, Herron E
Arch Gen Psychiatry. 1979 Nov;36(12):1283-94. doi: 10.1001/archpsyc.1979.01780120013001.
The ability of long-acting fluphenazine decanoate and oral fluphenazine hydrochloride to forestall relapse among newly discharge schizophrenic patients is examined in the context of high and low degrees of social therapy (ST). A total of 105 patients were randomly assigned to the various treatments and maintained under controlled conditions for two years or until relapse. Relapse rates for all treatments remained traditionally high. Relpase rates for long-acting fluphenazine decanoate and oral fluphenazine hydrochloride are nearly identical in the first year, indicating that drug noncompliance does not adequately explain early schizophrenic relapse. However, patients who received long-acting fluphenazine decanoate and ST have a reduced risk of relapse over time. Relapsers who received long-acting fluphenazine decanoate appeared more affectively disturbed than other relapsers, yet both groups were diagnostically and symptomatically equivalent prior to treatment. Personal discomfort and intrafamilial stress are important predictors.
在高、低程度社会治疗（ST）的背景下，研究了长效氟奋乃静癸酸酯和口服盐酸氟奋乃静在预防新出院精神分裂症患者复发方面的能力。总共105名患者被随机分配到各种治疗组，并在受控条件下维持两年或直至复发。所有治疗的复发率传统上仍然很高。长效氟奋乃静癸酸酯和口服盐酸氟奋乃静在第一年的复发率几乎相同，这表明药物不依从并不能充分解释早期精神分裂症复发。然而，接受长效氟奋乃静癸酸酯和社会治疗的患者随着时间推移复发风险降低。接受长效氟奋乃静癸酸酯的复发者比其他复发者在情感上似乎更受困扰，然而两组在治疗前在诊断和症状方面是相当的。个人不适和家庭内压力是重要的预测因素。
